| [1] |
Moskvina EA, Naskhletashvili DR, Bekyashev AK，et al.A clinical case of combined treatment of a patient with breast cancer and metastases to the brain and meninges[J]. Zh Vopr Neirokhir Im N N Burdenko, 2016，80(1): 83-87.
|
| [2] |
Morikawa A, Jordan L, Rozner R, et al.Characteristics and outcomes of patients with breast cancer with leptomeningeal metastasis[J]. Clin Breast Cancer, 2017，17(1): 23-28.
|
| [3] |
Park WY, Kim HJ, Kim K, et al.Intrathecal trastuzumab treatment in patients with breast cancer and leptomeningeal carcinomatosis[J]. Cancer Res Treat, 2016，48(2): 843-847.
|
| [4] |
Alnajar H, Rosen L, Javidiparsijani S, et al.Prognostic markers and histologic subtypes in patients with meningeal carcinomatosis in breast cancer[J]. Acta Cytol, 2017，61(2): 140-144.
|
| [5] |
马春华，姜镕，李金铎，等．肺癌脑膜转移的研究进展[J]. 中国肺癌杂志，2014，17(9): 695-700.
|
| [6] |
Rao R, Hoda SA, Marcus A, et al.Metastatic breast carcinoma in cerebrospinal fluid: acytopathological review of 15 cases[J]. Breast J, 2017，23(4): 456-460.
|
| [7] |
Lee DW, Lee KH, Kim JW, et al.Molecular targeted therapies for the treatment of leptomeningeal carcinomatosis：current evidence and future directions[J]. Int J Mol Sci, 2016，17(7)：1074.
|
| [8] |
Pan X, Lu Y, Wen L, et al.Gadobutrol-enhanced magnetic resonance imaging of meningeal carcinomatosis: case report with emphasis on early diagnosis[J]. BMC Neurol, 2016，16: 158.
|
| [9] |
Meng Z, Zhang Q, Hong K, et al.Clinical outcome and prognostic analysis of meningeal carcinomatosis treated by intrathecal chemotherapy[J]. Expert Rev Pharmacoecon Outcomes Res, 2018，18(4): 455-460.
|
| [10] |
Herrlinger U, Forschler H, Kuker W, et al.Leptomeningeal metastasis: survival and prognostic factors in 155 patients[J]. J Neurol Sci, 2004，223(2): 167-178.
|
| [11] |
Oechsle K, Lange-Brock V, Kruell A, et al.Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis[J]. J Cancer Res Clin Oncol, 2010，136(11): 1729-1735.
|
| [12] |
Grant R, Naylor B, Greenberg HS, et al.Clinical outcome in aggressively treated meningeal carcinomatosis[J]. Arch Neurol, 1994，51(5): 457-461.
|
| [13] |
Rudnicka H, Niwinska A, Murawska M．Breast cancer leptomeningeal metastasis--the role of multimodality treatment[J]. J Neurooncol, 2007，84(1): 57-62.
|
| [14] |
Siegal T, Lossos A, Pfeffer MR.Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy[J]. Neurology, 1994，44(8): 1463-1469.
|
| [15] |
Wang N, Bertalan MS, Brastianos PK.Leptomeningeal metastasis from systemic cancer: Review and update on management[J]. Cancer, 2018，124(1): 21-35.
|
| [16] |
Boogerd W, van den Bent MJ, Koehler PJ, et al.The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study[J]. Eur J Cancer, 2004，40(18): 2726-2733.
URL
|
| [17] |
Kak M, Nanda R, Ramsdale EE, et al.Treatment of leptomeningeal carcinomatosis: current challenges and future opportunities[J]. J Clin Neurosci, 2015，22(4): 632-637.
|
| [18] |
Li F, Tang SC.Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB)[J]. Genes Dis, 2017，4(1): 1-3.
|
| [19] |
O’Sullivan CC, Davarpanah NN, Abraham J, et al.Current challenges in the management of breast cancer brain metastases[J]. Semin Oncol, 2017，44(2): 85-100.
|
| [20] |
Andic F, Ors Y, Niang U, et al.Dosimetric comparison of conventional helmet-field whole-brain irradiation with three-dimensional conformal radiotherapy: dose homogeneity and retro-orbital area coverage[J]. Br J Radiol, 2009，82(974): 118-122.
|
| [21] |
Mack F, Baumert BG, Schafer N, et al.Therapy of leptomeningeal metastasis in solid tumors[J]. Cancer Treat Rev, 2016，43: 83-91.
|
| [22] |
Souchon R, Feyer P, Thomssen C, et al.Clinical recommendations of DEGRO and AGO on preferred standard palliative radiotherapy of bone and cerebral metastases, metastatic spinal cord compression, and leptomeningeal carcinomatosis in breast cancer[J]. Breast Care (Basel), 2010，5(6): 401-407.
|
| [23] |
Lee YC, Hsieh CC, Chuang JP, et al.The necessity of intrathecal chemotherapy for the treatment of breast cancer patients with leptomeningeal metastasis: A systematic review and pooled analysis[J]. Curr Probl Cancer, 2017，41(5): 355-370.
|
| [24] |
Jo JC, Kang MJ, Kim JE, et al.Clinical features and outcome of leptomeningeal metastasis in patients with breast cancer: a single center experience[J]. Cancer Chemother Pharmacol, 2013，72(1): 201-207.
|
| [25] |
Abouharb S, Ensor J, Loghin ME, et al.Leptomeningeal disease and breast cancer: the importance of tumor subtype[J]. Breast Cancer Res Treat, 2014，146(3): 477-486.
|
| [26] |
Gaviani P, Silvani A, Corsini E, et al.Neoplastic meningitis from breast carcinoma with complete response to liposomal cytarabine: case report[J]. Neurol Sci, 2009，30(3): 251-254.
URL
|
| [27] |
Lekovic G, Drazin D, Mak AC, et al.Cyberknife radiosurgery and concurrent intrathecal chemotherapy for leptomeningeal metastases: case report of prolonged survival of a HER-2＋ breast cancer patient status-post craniospinal irradiation[J]. Cureus, 2016，8(1): e453.
|
| [28] |
Butto A, Al-Holou WN, Junck L, et al.Fulminant chemical ventriculomeningitis following intrathecal liposomal cytarabine administration[J]. J Clin Neurosci, 2011，18(10): 1417-1418.
URL
|
| [29] |
Stemmler HJ, Schmitt M, Willems A, et al.Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier[J]. Anticancer Drugs, 2007，18(1): 23-28.
|
| [30] |
Hofer S, Mengele K, Stemmler HJ, et al.Intrathecal trastuzumab: dose matters[J]. Acta Oncol, 2012，51(7): 955-956.
URL
|
| [31] |
Torres S, Maralani P, Verma S．Activity of T-DM1 in HER-2 positive central nervous system breast cancer metastases[J]. BMJ Case Rep, 2014，2014：bcr2014205680.
|
| [32] |
Borges VF, Ferrario C, Aucoin N, et al.Tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2/HER2-positive metastatic breast cancer: a phase 1b clinical trial[J]. JAMA Oncol, 2018，4(9): 1214-1220.
|
| [33] |
Blair HA, Borges VF, Ferrario C, et al.Pyrotinib: first global approval[J]. Drugs, 2018，78(16): 1751-1755.
|
| [34] |
王金礼，王尧河，贾国丛．溶瘤病毒治疗乳腺癌的研究进展[J/CD]. 中华乳腺病杂志(电子版), 2014，8(05): 341-346.
|
| [35] |
Kuruppu D, Tanabe KK, Borges VF, et al.HSV-1 as a novel therapy for breast cancer meningeal metastases[J]. Cancer Gene Ther, 2015，22(10): 506-508.
|
| [36] |
Almajed MM, Esfahani K, Pelmus M, et al.Complete response and long-term survival of leptomeningeal carcinomatosis from breast cancer with maintenance endocrine therapy[J]. BMJ Case Rep, 2016，2016.
|
| [37] |
Roth P, Weller M．Management of neoplastic meningitis[J]. Chin Clin Oncol, 2015，4(2): 26.
|
| [38] |
Omuro AM, Lallana EC, Bilsky MH, et al.Ventriculoperitoneal shunt in patients with leptomeningeal metastasis[J]. Neurology, 2005，64(9): 1625-1627.
|
| [39] |
Weller M, Stupp R, Wick W．Epilepsy meets cancer: when, why, and what to do about it？[J]. Lancet Oncol, 2012，13(9): e375-382.
URL
|